Specifically, these mechanisms of action cover multiple aspects, such as activation of the cAMP-PKA signaling pathway, inhibition of pro-inflammatory cytokine release, and also activation of the AMPK signaling pathway, promoting the expression of anti-inflammatory genes, and regulation of macrophage function [26]
Bilchick said GLP-1 drugs have an anti-inflammatory effect, which may what led to the lower AFib rates in GLP-1 patients
Many proteins are enzymes that catalyze the chemical reactions in metabolism
The drugmaker noted that the FDAs warning letter acknowledges the significant measures Novo Nordisk has taken over the past year meant to ensure full compliance with reporting requirements
The risk was 0.2% in people taking GLP-1s and 0.1% in those who didnt
Log in below to join the conversation.